Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 40

1.

Multimodal quantitative imaging of brain cancer in cultured cells.

Feng X, Muzikansky A, Ross AH, Hamblin MR, Jermain PR, Yaroslavsky AN.

Biomed Opt Express. 2019 Jul 29;10(8):4237-4248. doi: 10.1364/BOE.10.004237. eCollection 2019 Aug 1.

2.

ER stress in temozolomide-treated glioblastomas interferes with DNA repair and induces apoptosis.

Weatherbee JL, Kraus JL, Ross AH.

Oncotarget. 2016 Jul 12;7(28):43820-43834. doi: 10.18632/oncotarget.9907.

3.

The PTEN Tumor Suppressor Forms Homodimers in Solution.

Heinrich F, Chakravarthy S, Nanda H, Papa A, Pandolfi PP, Ross AH, Harishchandra RK, Gericke A, Lösche M.

Structure. 2015 Oct 6;23(10):1952-1957. doi: 10.1016/j.str.2015.07.012. Epub 2015 Aug 20.

4.

Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma in vitro and in vivo.

Karpel-Massler G, Shu C, Chau L, Banu M, Halatsch ME, Westhoff MA, Ramirez Y, Ross AH, Bruce JN, Canoll P, Siegelin MD.

Oncotarget. 2015 Jun 10;6(16):14507-21.

5.

Biophysical methods for the characterization of PTEN/lipid bilayer interactions.

Harishchandra RK, Neumann BM, Gericke A, Ross AH.

Methods. 2015 May;77-78:125-35. doi: 10.1016/j.ymeth.2015.02.004. Epub 2015 Feb 16. Review.

6.

Evaluation of novel imidazotetrazine analogues designed to overcome temozolomide resistance and glioblastoma regrowth.

Ramirez YP, Mladek AC, Phillips RM, Gynther M, Rautio J, Ross AH, Wheelhouse RT, Sakaria JN.

Mol Cancer Ther. 2015 Jan;14(1):111-9. doi: 10.1158/1535-7163.MCT-14-0113. Epub 2014 Oct 28.

7.

A unified nomenclature and amino acid numbering for human PTEN.

Pulido R, Baker SJ, Barata JT, Carracedo A, Cid VJ, Chin-Sang ID, Davé V, den Hertog J, Devreotes P, Eickholt BJ, Eng C, Furnari FB, Georgescu MM, Gericke A, Hopkins B, Jiang X, Lee SR, Lösche M, Malaney P, Matias-Guiu X, Molina M, Pandolfi PP, Parsons R, Pinton P, Rivas C, Rocha RM, Rodríguez MS, Ross AH, Serrano M, Stambolic V, Stiles B, Suzuki A, Tan SS, Tonks NK, Trotman LC, Wolff N, Woscholski R, Wu H, Leslie NR.

Sci Signal. 2014 Jul 1;7(332):pe15. doi: 10.1126/scisignal.2005560.

8.

PI3K and Bcl-2 inhibition primes glioblastoma cells to apoptosis through downregulation of Mcl-1 and Phospho-BAD.

Pareja F, Macleod D, Shu C, Crary JF, Canoll PD, Ross AH, Siegelin MD.

Mol Cancer Res. 2014 Jul;12(7):987-1001. doi: 10.1158/1541-7786.MCR-13-0650. Epub 2014 Apr 22.

9.

Cholesterol stabilizes fluid phosphoinositide domains.

Jiang Z, Redfern RE, Isler Y, Ross AH, Gericke A.

Chem Phys Lipids. 2014 Sep;182:52-61. doi: 10.1016/j.chemphyslip.2014.02.003. Epub 2014 Feb 17.

10.

Glioblastoma multiforme therapy and mechanisms of resistance.

Ramirez YP, Weatherbee JL, Wheelhouse RT, Ross AH.

Pharmaceuticals (Basel). 2013 Nov 25;6(12):1475-506. doi: 10.3390/ph6121475.

11.

PtdIns(4,5)P2-mediated cell signaling: emerging principles and PTEN as a paradigm for regulatory mechanism.

Gericke A, Leslie NR, Lösche M, Ross AH.

Adv Exp Med Biol. 2013;991:85-104. doi: 10.1007/978-94-007-6331-9_6. Review.

12.

Membrane association of the PTEN tumor suppressor: molecular details of the protein-membrane complex from SPR binding studies and neutron reflection.

Shenoy S, Shekhar P, Heinrich F, Daou MC, Gericke A, Ross AH, Lösche M.

PLoS One. 2012;7(4):e32591. doi: 10.1371/journal.pone.0032591. Epub 2012 Apr 10.

13.

Resolution of inflammation by N-arachidonoylglycine.

Burstein SH, McQuain CA, Ross AH, Salmonsen RA, Zurier RE.

J Cell Biochem. 2011 Nov;112(11):3227-33. doi: 10.1002/jcb.23245.

14.

Exploiting the mitochondrial unfolded protein response for cancer therapy in mice and human cells.

Siegelin MD, Dohi T, Raskett CM, Orlowski GM, Powers CM, Gilbert CA, Ross AH, Plescia J, Altieri DC.

J Clin Invest. 2011 Apr;121(4):1349-60. doi: 10.1172/JCI44855.

15.

Gamma-secretase inhibitors enhance temozolomide treatment of human gliomas by inhibiting neurosphere repopulation and xenograft recurrence.

Gilbert CA, Daou MC, Moser RP, Ross AH.

Cancer Res. 2010 Sep 1;70(17):6870-9. doi: 10.1158/0008-5472.CAN-10-1378. Epub 2010 Aug 24.

16.

A mutant form of PTEN linked to autism.

Redfern RE, Daou MC, Li L, Munson M, Gericke A, Ross AH.

Protein Sci. 2010 Oct;19(10):1948-56. doi: 10.1002/pro.483.

17.

Global targeting of subcellular heat shock protein-90 networks for therapy of glioblastoma.

Siegelin MD, Plescia J, Raskett CM, Gilbert CA, Ross AH, Altieri DC.

Mol Cancer Ther. 2010 Jun;9(6):1638-46. doi: 10.1158/1535-7163.MCT-10-0097. Epub 2010 May 25.

18.

A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications.

Sheng Z, Li L, Zhu LJ, Smith TW, Demers A, Ross AH, Moser RP, Green MR.

Nat Med. 2010 Jun;16(6):671-7. doi: 10.1038/nm.2158. Epub 2010 May 23.

19.

Sorafenib exerts anti-glioma activity in vitro and in vivo.

Siegelin MD, Raskett CM, Gilbert CA, Ross AH, Altieri DC.

Neurosci Lett. 2010 Jul 12;478(3):165-70. doi: 10.1016/j.neulet.2010.05.009. Epub 2010 May 12. Erratum in: Neurosci Lett. 2013 Feb 28;539:93.

20.

Clinically relevant doses of chemotherapy agents reversibly block formation of glioblastoma neurospheres.

Mihaliak AM, Gilbert CA, Li L, Daou MC, Moser RP, Reeves A, Cochran BH, Ross AH.

Cancer Lett. 2010 Oct 28;296(2):168-77. doi: 10.1016/j.canlet.2010.04.005.

Supplemental Content

Loading ...
Support Center